Relationship of Selected Adipokines with Markers of Vascular Damage in Patients with Type 2 Diabetes
BACKGROUND: In this study we compared levels of selected adipokines between patients with type 2 diabetes (T2D) and healthy individuals and we determined their relationship with early vascular damage markers.
METHODS: Seventy-seven subjects: 56 patients with T2D (34 men and 22 women) and 21 healthy controls (8 men and 13 women) were examined in this cross-sectional study. Selected adipokines [adiponectin, adipocyte fatty acid-binding protein (A-FABP), fibroblast growth factor 21 (FGF-21), C1q/TNF-related protein 9 (CTRP-9), and allograft inflammatory factor-1 (AIF-1)] with possible cardiovascular impact were measured in all participants. To identify markers of vascular damage von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1) and arterial stiffness parameters were examined in all the subjects.
RESULTS: When compared with healthy controls, T2D had significantly higher levels of A-FABP [50.0 (38.1-68.6) vs. 28.6 (23.6-32.9) ng/mL, P < 0.0001] and lower levels of adiponectin [5.9 (4.3-9.0) vs. 11.3 (8.7-14.8) μg/mL, P < 0.0001]. Differences in other adipokines were not statistically significant. Adiponectin level correlated negatively with vWF levels (ρ = -0.29, P < 0.05) and PAI-1 (ρ = -0.36, P < 0.05) and A-FABP positively with vWF (ρ = 0.61, P < 0.05) and PAI-1 (ρ = 0.47, P < 0.05) and augmentation index (ρ = 0.26, P < 0.05). Multivariate regression analysis showed independent association between A-FABP and vWF (b = 0.24, P < 0.05).
CONCLUSIONS: Patients with T2D have significantly higher levels of A-FABP and lower levels of adiponectin. These adipokines correlate with indicators of vascular damage and could contribute to cardiovascular risk in patients with T2D. A-FABP may participate in direct endothelium damage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Metabolic syndrome and related disorders - 16(2018), 5 vom: 01. Juni, Seite 246-253 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Spurná, Jaromíra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADIPOQ protein, human |
|---|
| Anmerkungen: |
Date Completed 10.05.2019 Date Revised 10.05.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/met.2017.0179 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283651369 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283651369 | ||
| 003 | DE-627 | ||
| 005 | 20231225041402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/met.2017.0179 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0945.xml |
| 035 | |a (DE-627)NLM283651369 | ||
| 035 | |a (NLM)29717906 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Spurná, Jaromíra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relationship of Selected Adipokines with Markers of Vascular Damage in Patients with Type 2 Diabetes |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2019 | ||
| 500 | |a Date Revised 10.05.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: In this study we compared levels of selected adipokines between patients with type 2 diabetes (T2D) and healthy individuals and we determined their relationship with early vascular damage markers | ||
| 520 | |a METHODS: Seventy-seven subjects: 56 patients with T2D (34 men and 22 women) and 21 healthy controls (8 men and 13 women) were examined in this cross-sectional study. Selected adipokines [adiponectin, adipocyte fatty acid-binding protein (A-FABP), fibroblast growth factor 21 (FGF-21), C1q/TNF-related protein 9 (CTRP-9), and allograft inflammatory factor-1 (AIF-1)] with possible cardiovascular impact were measured in all participants. To identify markers of vascular damage von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1) and arterial stiffness parameters were examined in all the subjects | ||
| 520 | |a RESULTS: When compared with healthy controls, T2D had significantly higher levels of A-FABP [50.0 (38.1-68.6) vs. 28.6 (23.6-32.9) ng/mL, P < 0.0001] and lower levels of adiponectin [5.9 (4.3-9.0) vs. 11.3 (8.7-14.8) μg/mL, P < 0.0001]. Differences in other adipokines were not statistically significant. Adiponectin level correlated negatively with vWF levels (ρ = -0.29, P < 0.05) and PAI-1 (ρ = -0.36, P < 0.05) and A-FABP positively with vWF (ρ = 0.61, P < 0.05) and PAI-1 (ρ = 0.47, P < 0.05) and augmentation index (ρ = 0.26, P < 0.05). Multivariate regression analysis showed independent association between A-FABP and vWF (b = 0.24, P < 0.05) | ||
| 520 | |a CONCLUSIONS: Patients with T2D have significantly higher levels of A-FABP and lower levels of adiponectin. These adipokines correlate with indicators of vascular damage and could contribute to cardiovascular risk in patients with T2D. A-FABP may participate in direct endothelium damage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a adipokines | |
| 650 | 4 | |a arterial stiffness | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a ADIPOQ protein, human |2 NLM | |
| 650 | 7 | |a Adipokines |2 NLM | |
| 650 | 7 | |a Adiponectin |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a FABP4 protein, human |2 NLM | |
| 650 | 7 | |a Fatty Acid-Binding Proteins |2 NLM | |
| 700 | 1 | |a Karásek, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kubíčková, Veronika |e verfasserin |4 aut | |
| 700 | 1 | |a Goldmannová, Dominika |e verfasserin |4 aut | |
| 700 | 1 | |a Krystyník, Ondřej |e verfasserin |4 aut | |
| 700 | 1 | |a Schovánek, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Zadražil, Josef |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Metabolic syndrome and related disorders |d 2003 |g 16(2018), 5 vom: 01. Juni, Seite 246-253 |w (DE-627)NLM175065497 |x 1557-8518 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:5 |g day:01 |g month:06 |g pages:246-253 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/met.2017.0179 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2018 |e 5 |b 01 |c 06 |h 246-253 | ||